Saturday 17 October 2026 Export EOLS’s income statement to Excel — free account

Evolus, Inc.

EOLS Healthcare Drug Manufacturers Specialty & Generic

Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

7.10 0.47 −6.21%

Follow EOLS

Alert me

Market cap: $500.0M
P/E: 0.0×
Fwd P/E: −13.4×
Dividend yield: —
F-score: 3/9
Altman Z: −1.87
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	—	2	—	—	—	—	—	1	—

Insider Ownership 12.27%

Capital & Financial Ratios $m

Market Cap 500.00

Revenue 316.49

Net Income (34.33)

Free Cash Flow (21.90)

Net Debt 111.57

Current Ratio 1.70

Debt/Equity (5.07)

P/E ratio 0.00

Fwd P/E (13.40)

P/S ratio 1.48

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 89.18%

Next Y EPS Growth 790.53%

Next Y revenue growth 12.46%

Next 5Y EPS Growth 16.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.51%

10-year low 10-year high

EV/Sales against its own 10 years 11.91%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	63	87	54	45
Receivables	31	48	55	62
Inventory	11	12	27	41
Other	2	1	4	15
	112	151	143	168

	2023	2024	2025	Q'26
Payables	4	9	23	44
ST’ Debt	—	—	—	—
Other	9	11	13	1
	48	63	75	99

Compound Annual Growth %

	10y	5y	3y
Sales	—	39.36%	25.98%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	73	84	—	—	—
’25	69	69	69	90	297
’24	59	67	61	79	266
’23	42	49	50	61	202
’22	34	37	34	44	149
’21	12	26	27	35	100
’20	10	8	18	21	57

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(4)	—	—	—
’25	(16)	(25)	(15)	13	(42)
’24	(11)	(6)	(6)	5	(18)
’23	(21)	(13)	(1)	1	(34)
’22	(38)	(21)	(17)	(9)	(85)
’21	(8)	16	(32)	(9)	(33)
’20	(28)	(14)	(14)	(2)	(58)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(4)	—	—	—
’25	(17)	(27)	(17)	11	(51)
’24	(11)	(8)	(7)	3	(23)
’23	(21)	(14)	(1)	0	(36)
’22	(38)	(21)	(18)	(10)	(88)
’21	(9)	16	(32)	(9)	(34)
’20	(29)	(15)	(14)	(3)	(61)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.12)	—	—	—
’25	(0.30)	(0.27)	(0.24)	0.00	(0.80)
’24	(0.22)	(0.18)	(0.30)	(0.11)	(0.81)
’23	(0.26)	(0.32)	(0.30)	(0.21)	(1.08)
’22	(0.31)	(0.42)	(0.36)	(0.23)	(1.33)
’21	0.16	(0.31)	(0.35)	(0.33)	(0.94)
’20	(0.59)	(0.63)	(0.34)	(3.28)	(4.83)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	6.75	11.34	2.85	3.06	5.06	7.07	9.80	5.71	Analyst estimates 2026–2028 Powerpack
	High	—	—	39.50	30.25	13.75	17.38	14.34	11.49	17.82	17.12
People
People	Employees	22	21	70	235	119	167	215	273	332	334
	Revenue/emp, $m	0.00	0.00	0.00	0.15	0.48	0.60	0.69	0.74	0.80	0.89
Income, $m
Income, $m	Revenue	—	—	—	35	57	100	149	202	266	297
	Gross margin, %	0.00	0.00	0.00	77.05	67.64	56.32	60.41	68.08	68.46	66.33
	EBT	(20)	(12)	(47)	(105)	(163)	(47)	(74)	(62)	(50)	(51)
	EBT margin, %	0.00	0.00	0.00	(300.82)	(288.18)	(46.92)	(50.01)	(30.44)	(18.69)	(17.15)
	Net income	(20)	(4)	(47)	(90)	(163)	(47)	(74)	(62)	(50)	(52)
	Depreciation	0	0	1	6	10	8	6	7	7	10
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	1.24	1.68	2.00	2.65	3.55	4.29	4.61
	Earnings	(1.21)	(0.27)	(1.92)	(3.19)	(4.83)	(0.94)	(1.33)	(1.08)	(0.81)	(0.80)
	Cash flow	(0.80)	(0.80)	(1.05)	(3.31)	(1.72)	(0.67)	(1.51)	(0.60)	(0.29)	(0.66)
	Capex	0.00	0.00	0.00	(0.16)	(0.09)	(0.02)	(0.05)	(0.03)	(0.08)	(0.13)
	Free cash flow	(0.80)	(0.80)	(1.05)	(3.47)	(1.81)	(0.69)	(1.57)	(0.63)	(0.37)	(0.79)
	Book value	(0.43)	(4.57)	3.46	2.81	(2.16)	1.65	0.33	(0.36)	0.09	(0.36)
	Shares, m	17	17	24	28	34	50	56	57	62	64
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	2.00	3.25	2.95	2.81	2.57	1.44
	P/B	—	—	—	4.33	0.00	3.96	23.73	0.00	123.99	0.00
	EV/Sales	—	—	—	0.00	2.13	3.24	3.58	3.47	2.98	2.00
	EV/FCF	—	—	—	(2.95)	(1.98)	(9.41)	(6.05)	(19.66)	(34.77)	(11.74)
Cash, $m
Cash, $m	Operating cash flow	(13)	(13)	(26)	(93)	(58)	(33)	(85)	(34)	(18)	(42)
	Capex	—	—	0	(5)	(3)	(1)	(3)	(2)	(5)	(8)
	Free cash flow	(13)	(13)	(26)	(98)	(61)	(34)	(88)	(36)	(23)	(51)
Balance, $m
Balance, $m	Working capital	(63)	(140)	89	128	(53)	121	54	64	88	68
	Total debt	60	73	17	75	115	71	72	120	122	146
	Net debt	60	73	(76)	(55)	7	(75)	18	58	35	92
	Shareholders’ equity	(7)	(76)	84	79	(73)	82	18	(21)	6	(23)
Returns, %
Returns, %	ROA	(25.27)	(3.90)	(28.92)	(43.68)	(72.53)	(20.07)	(34.18)	(33.62)	(23.92)	(22.53)
	ROIC	(23.78)	0.00	(354.89)	(253.85)	0.00	(405.63)	(112.00)	(83.54)	(53.67)	(29.51)
	ROE	(819.65)	10.84	(1,060.22)	(109.90)	(5,016.56)	(1,049.79)	(148.27)	5,633.33	664.86	587.36

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COLL Collegium Pharmaceutical, Inc.	$754.6M	15.2×	12.5×	+6.32% (above 0%: growing)	n/m	−2.14% (below 0%: shrinking)	55.18%	1.85%	Compare
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
Median of peers	$489.4M	15.2×	—	+22.73%	—	−11.24%	48.05%	(16.53%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Evolus, Inc. (EOLS) key facts

Concern: Evolus, Inc. reported a net loss of $51.6 million, or a loss of $0.80 per share, for fiscal 2025.
Strength: Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
Evolus, Inc. (EOLS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, EOLS traded at $7.10, a market capitalization of $500.0 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.5× sales.
Return on equity was 587.4% and debt-to-equity -5.07.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −1.87 (distress zone) for fiscal 2025.